Patient information
Welcome to our online platform about PRIME-CKD. A project that must lead to new therapies for the treatment of CKD. Not only will we inform you about the progress of PRIME-CKD with latest research findings, breakthroughs, and scientific publications. We are also very dedicated to demonstrate how we work together and how we involve everyone that can make the best possible pharmaceutical care for CKD patients a reality.
It was a breakthrough in treatment for people with chronic kidney damage a few years ago. By chance it was discovered that kidney patients benefit significantly from medications originally developed for people with diabetes to lower blood sugar levels. The so-called SGLT2 inhibitors slow down the decline of kidney function and sometimes even halt it entirely – even in individuals without diabetes.
“Large studies show that these medicines work well,” says Hiddo Lambers Heerspink, professor of clinical pharmacology at the UMC Groningen. “But this is not or insufficiently the case in a number of people with chronic kidney damage. Patients also sometimes suffer from serious side effects. Why do people react differently to the same medications? That’s what we are going to investigate.”
